
-
Vir Biotechnology NasdaqGS:VIR Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Location: 1800 Owens Street, San Francisco, CA, 94158, United States | Website: https://www.vir.bio | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
11.89M
Cash
801.7M
Avg Qtr Burn
-103.8M
Short % of Float
11.64%
Insider Ownership
22.66%
Institutional Own.
79.13%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tobevibart + Elebsiran Details Infectious disease, Hepatitis Delta Virus | Phase 3 Data readout | |
Sotrovimab VIR-7831 (GSK4182136) Details COVID-19, Infectious disease | Phase 3 Update | |
Tobevibart (VIR-3434) + Elebsiran (VIR-2218) Details Infectious disease, Hepatitis B | Phase 2 Data readout | |
VIR-3434 +/- VIR-2218 +/- PEG-IFNα Details Infectious disease, Hepatitis B | Phase 2 Data readout | |
VIR-2482 (Universal prophylaxis) Details Influenza, Infectious disease | Phase 2 Update | |
VIR-5818 + Pembrolizumab Details Cancer, HER2-expressing cancers, Metastatic breast cancer, Metastatic colorectal cancer | Phase 1 Data readout | |
VIR-5500 Details Metastatic castration resistant prostate cancer (mCRPC) | Phase 1 Data readout | |
VIR-1388 (HVTN 142) Details Infectious disease, Human immunodeficiency virus, Vaccine | Phase 1 Data readout | |
VIR-5525 Details Cancer, Head and neck squamous cell carcinoma, Non-small cell lung carcinoma, Metastatic colorectal cancer | Phase 1 Initiation | |
VIR-1111 Details Infectious disease, Human immunodeficiency virus, Vaccine | Failed Discontinued | |
Sotrovimab VIR-7831 (GSK4182136) Details COVID-19, Infectious disease | Failed Discontinued |